1009 Results

People

  1. Motzer
    Motzer
  2. O'Reilly
    O'Reilly
  3. Kris
    Kris
  4. Aghajanian
    Aghajanian
  5. Hudis
    Hudis
  6. Bajorin
    Bajorin
  7. Kelsen
    Kelsen
  8. Ginsberg
    Ginsberg
  9. Krug
    Krug
  10. Scher
    Scher

Groups

  1. Department of Medicine (716)
  2. Solid Tumor Oncology Division (483)
  3. Hematologic Malignancies, Division of (277)
  4. Center for Hematologic Malignancies (224)
  5. Survivorship Research (151)
  6. Genitourinary Oncology Service (136)
  7. Epidemiology and Biostatistics (119)
  8. Radiology, Department of (111)
  9. Biostatistics Service (109)
  10. GSK Faculty (104)
  1. "anemia"
Formats
  1. Journal Article (926)
  2. Review (42)
  3. Research Letter (15)
  4. Conference Paper (12)
  5. Editorial (4)
  6. Guidelines (3)
  7. Miscellaneous (3)
  8. Correspondence (2)
  9. Book Section (1)
  10. Meeting Abstract (1)
Groups
  1. Department of Medicine (716)
  2. Solid Tumor Oncology Division (483)
  3. Hematologic Malignancies, Division of (277)
  4. Center for Hematologic Malignancies (224)
  5. Survivorship Research (151)
  6. Genitourinary Oncology Service (136)

More Groups

People
  1. Robert Motzer (55)
  2. Eileen O'Reilly (35)
  3. Mark Kris (32)
  4. Carol Aghajanian (31)
  5. Clifford Hudis (31)
  6. Dean Bajorin (29)

More People

Years
  1. 2025 (41)
  2. 2024 (99)
  3. 2023 (56)
  4. 2022 (45)
  5. 2021 (25)
  6. 2020 (62)

More Years

Publications
  1. Journal of Clinical Oncology (69)
  2. Cancer (50)
  3. Clinical Cancer Research (49)
  4. Lancet Oncology (47)
  5. Gynecologic Oncology (34)
  6. Blood (29)

More Publications

Publishers
  1. Elsevier Inc. (147)
  2. Springer (90)
  3. Elsevier Science, Inc. (83)
  4. American Society of Clinical Oncology (74)
  5. Wiley Blackwell (65)
  6. Nature Publishing Group (61)

More Publishers

Results (1009)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Brentuximab vedotin with AVD for stage II–IV HIV-related Hodgkin lymphoma (AMC 085): Phase 2 results from an open-label, single arm, multicentre phase 1/2 trial
    Journal Article

    Rubinstein, P. G.; Moore, P. C.; Bimali, M.; Lee, J. Y.; Rudek, M. A.; Chadburn, A.; Ratner, L.; Henry, D. H.; Cesarman, E.; DeMarco, C. E.; more...
    The Lancet Haematology (2023)

    Fulltext@MSK | Save
  • Disseminated intravascular coagulation after cryoablation for metastatic pancreatic cancer: A case report
    Journal Article

    Dulu, A.; Tayban, Y.; Delaleu, J.; Cornelis, F. H.; Pastores, S. M.
    AME Medical Journal (2023)

    Fulltext@MSK | Save
  • Entospletinib with decitabine in acute myeloid leukemia with mutant TP53 or complex karyotype: A phase 2 substudy of the Beat AML Master Trial
    Journal Article

    Duong, V. H.; Ruppert, A. S.; Mims, A. S.; Borate, U.; Stein, E. M.; Baer, M. R.; Stock, W.; Kovacsovics, T.; Blum, W.; Arellano, M. L.; more...
    Cancer (2023)

    Fulltext@MSK | Save
  • Pembrolizumab alone and pembrolizumab plus chemotherapy in previously treated, extrapulmonary poorly differentiated neuroendocrine carcinomas
    Journal Article

    Raj, N.; Chan, J. A.; Wang, S. J.; Aggarwal, R. R.; Calabrese, S.; DeMore, A.; Fong, L.; Grabowsky, J.; Hope, T. A.; Kolli, K. P.; more...
    British Journal of Cancer (2023)

    Fulltext@MSK | Save
  • A phase 2 study of dasatinib in recurrent clear cell carcinoma of the ovary, fallopian tube, peritoneum or endometrium: NRG Oncology/Gynecologic Oncology Group study 0283
    Journal Article

    O'Cearbhaill, R. E.; Miller, A.; Soslow, R. A.; Lankes, H. A.; DeLair, D.; Segura, S.; Chavan, S.; Zamarin, D.; DeBernardo, R.; Moore, K.; more...
    Gynecologic Oncology (2023)

    Fulltext@MSK | Save
  • Asciminib monotherapy in patients with CML-CP without BCR::ABL1 T315I mutations treated with at least two prior TKIs: 4-year phase 1 safety and efficacy results
    Journal Article

    Mauro, M. J.; Hughes, T. P.; Kim, D. W.; Rea, D.; Cortes, J. E.; Hochhaus, A.; Sasaki, K.; Breccia, M.; Talpaz, M.; Ottmann, O.; more...
    Leukemia (2023)

    Fulltext@MSK | Save
  • Targeting RARA overexpression with tamibarotene, a potent and selective RARα agonist, is a novel approach in AML
    Journal Article

    de Botton, S.; Cluzeau, T.; Vigil, C.; Cook, R. J.; Rousselot, P.; Rizzieri, D. A.; Liesveld, J. L.; Fenaux, P.; Braun, T.; Banos, A.; more...
    Blood Advances (2023)

    Fulltext@MSK | Save
  • Dual targeting of CD19 and CD22 with bicistronic CAR-T cells in patients with relapsed/refractory large B-cell lymphoma
    Journal Article

    Roddie, C.; Lekakis, L. J.; Marzolini, M. A. V.; Ramakrishnan, A.; Zhang, Y.; Hu, Y.; Peddareddigari, V. G. R.; Khokhar, N.; Chen, R.; Basilico, S.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Bridging radiation rapidly and effectively cytoreduces high-risk relapsed/refractory aggressive B cell lymphomas prior to chimeric antigen receptor T cell therapy
    Journal Article

    Hubbeling, H.; Silverman, E. A.; Michaud, L.; Tomas, A. A.; Shouval, R.; Flynn, J.; Devlin, S.; Wijetunga, N. A.; Tringale, K. R.; Batlevi, C.; more...
    Transplantation and Cellular Therapy (2023)

    Fulltext@MSK | Save
  • Clinicopathologic outcomes of preoperative targeted therapy in patients with clinical stage I to III non–small cell lung cancer
    Conference Paper

    Lengel, H. B.; Zheng, J.; Tan, K. S.; Liu, C. C.; Park, B. J.; Rocco, G.; Adusumilli, P. S.; Molena, D.; Yu, H. A.; Riely, G. J.; more...
    Mosby Elsevier (2023)

    Fulltext@MSK | Save